Gemcitabine

ArtNr	HY-17026-500mg
Hersteller	MedChem Express
CAS-Nr.	95058-81-4
Menge	500 mg
Quantity options	100 mg 10mM/1mL 1 g 200 mg 500 mg 5 g
Kategorie	Oncology Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Breast Cancer
Typ	Inhibitors
Clon	N/A
Specific against	other
Purity	99.96
Formula	C9H11F2N3O4
Citations	Acta Biochim Biophys Sin. 2021 Jan 12;gmaa177.<br/>Acta Pharmacol Sin. 2023 Dec 6.<br/>Adv Mater. 2021 May;33(18):e2100949.<br/>Adv Sci (Weinh). 2023 Feb 19;e2206004.<br/>Adv Sci (Weinh). 2023 Oct 22:e2302498.<br/>Adv Sci (Weinh). 2023 Sep 3;e2303872.<br/>Aging. 2020 Aug 28;12(16):16304-16325.<br/>Am J Cancer Res. 2020 Nov 1;10(11):3896-3910.<br/>Am J Cancer Res. 2020 Apr 1;10(4):1182-1193.<br/>Arch Toxicol. 2023 Dec;97(12):3209-3226.<br/>ÁREA DE FARMACIA Y TECNOLOGÍA FARMACÉUTICA. DEPARTAMENTO DE INGENIERÍA. 2020 Oct.<br/>Biochem Pharmacol. 2020 Jun 6;114085. <br/>Biochem Pharmacol. 2021 Oct 18;193:114813.<br/>Biochem Pharmacol. 2024 Apr 24:116234.<br/>Biol Pharm Bull. 2021 Dec 22.<br/>Biomaterials. 16 September 2022.<br/>Biomed Pharmacother. 2019 Sep;117:109185.<br/>Biomed Pharmacother. 2022 Feb 11;148:112713.<br/>Biomed Pharmacother. 2023 Aug 31;166:115389.<br/>bioRxiv. 2023 Feb 28.<br/>bioRxiv. 2023 Feb 7.<br/>bioRxiv. 2023 Sep 5.<br/>Breast Cancer Res Treat. 2023 May 19.<br/>Cancer Lett. 2022 Jun 28;536:215651.<br/>Cancer Lett. 2022 Nov 24;216023.<br/>Cancer Med. 2019 Oct;8(13):5903-5915.<br/>Cell Death Discov. 2021 May 1;7(1):89.<br/>Cell Mol Life Sci. 2021 Oct 13.<br/>Cell Prolif. 2021 Apr 1;e13038.<br/>Cell Rep Med. 2023 Jan 10;100911.<br/>Cell Rep Med. 2023 Oct 17;4(10):101234.<br/>Cell Rep. 2022 Aug 16;40(7):111194.<br/>Cell Rep. 2024 Apr 23;43(4):114088.<br/>Cell Res. 2020 Jul;30(7):574-589.<br/>Chem Biol Interact. 2018 Jun 25;290:44-51.<br/>Chem Eng J. 2023 Nov 17, 147466.<br/>Chinese Chemical Letters. <br/>Chinese Pharmacological Bulletin. 2017, 33(6): 788-792.<br/>Clin Transl Oncol. 2022 Jul 19.<br/>DNA Cell Biol. 2021 Dec 13.<br/>Elife. 2022 May 3;11:e69255.<br/>Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):649-659. <br/>Exp Cell Res. 2020 Dec 1;397(1):112335.<br/>Front Oncol. 2021 Jul 13;11:704042.<br/>Gastroenterology. 2021 Nov;161(5):1601-1614.e23.<br/>Hepatology. 2019 May;69(5):1995-2012. <br/>Immun Inflamm Dis. 2023 Jun 14.<br/>Inflamm Res. 2022 Oct 27.<br/>Int Immunopharmacol. 2023 Jul 27;123:110709.<br/>Int J Biol Sci. 2022 Jul 4;18(11):4301-4315.<br/>Int J Biol Sci. 2022; 18(1):43-64.<br/>Int J Clin Exp Pathol. 2017;10(3):3033-3042.<br/>Int J Hyperthermia. 2024 Feb 12;41(1):2316085.<br/>Int J Med Sci. 2022; 19(2): 286-298.<br/>Invest New Drugs. 2022 Jan 4.<br/>iScience. 6 September 2022, 105081.<br/>J Biol Chem. 2017 Jun 2;292(22):9136-9149.<br/>J Biol Chem. 2023 Jun 28;104984.<br/>J Biomed Inform. 2023 May 15;104383.<br/>J Cannabis Res. 2024 May 8;6(1):22.<br/>J Clin Invest. 2024 Mar 7:e172716.<br/>J Control Release. 2023 Aug 4;361:161-177.<br/>J Ethnopharmacol. 2024 Mar 19:328:118075.<br/>J Exp Clin Cancer Res. 2021 Nov 25;40(1):373.<br/>J Exp Clin Cancer Res. 2022 Oct 5;41(1):293.<br/>J Exp Clin Cancer Res. 2023 May 4;42(1):111.<br/>J Mater Chem B. 2023 Oct 11.<br/>J Mol Med (Berl). 2019 Aug;97(8):1183-1193.<br/>J Nanobiotechnology. 2022 Jul 6;20(1):315.<br/>J Pancreatol. 2023 Dec 12.<br/>J Transl Med. 2023 Nov 21;21(1):838.<br/>J Transl Med. 2024 Jan 13;22(1):55.<br/>Mol Cancer. 2023 Dec 4;22(1):195.<br/>Mol Cancer. 2024 Apr 29;23(1):86.<br/>Mol Carcinog. 2024 Jan 30.<br/>Mol Immunol. 2019 May;109:140-148. <br/>Mol Pharm. 2021 Jun 2.<br/>Molecules. 2022, 27(20), 6849.<br/>Nat Med. 2024 Mar;30(3):749-761.<br/>Nature. 2019 Oct;574(7777):264-267. <br/>Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622.<br/>Onco Targets Ther. 2020 Sep 28;13:9543-9558.<br/>Oncogene. 2023 Aug 31.<br/>Oncol Lett. June 30, 2021.<br/>Oncol Rep. 2022 Feb;47(2):33.<br/>Oxid Med Cell Longev. 2022 Sep 29;2022:3243647.<br/>Patent. US20210260092A1.<br/>Patent. US20220362387A1.<br/>Pharmacol Res. 2024 May 9:204:107208.<br/>Phytomedicine. 2024 Apr 26:155656.<br/>Phytomedicine. 2024 Mar 11, 155527.<br/>Phytomedicine. 6 July 2022, 154323.<br/>Phytother Res. 2022 Aug;36(8):3313-3324.<br/>Redox Biol. 2021 Jan;38:101807.<br/>Redox Biol. 2024 May 17:73:103200.<br/>Research Square Preprint. 2021 Aug.<br/>Research Square Preprint. 2021 Nov.<br/>Research Square Preprint. 2024 Jan 8.<br/>Research Square Print. October 6th, 2022.<br/>RSC Adv. 2022, 12, 28104-28112.<br/>Sci Transl Med. 2021 Jan 20;13(577):eaba7401.<br/>SLAS Discov. 2018 Aug;23(7):687-696. <br/>Stem Cells Int. 2023 Jan 30.<br/>Surgery. 2024 Jan 31:S0039-6060(23)00963-7.<br/>Technol Cancer Res Treat. 2024 Jan-Dec:23:15330338241241935.<br/>Theranostics. 2021 Mar 24;11(12):5650-5674.<br/>Transl Oncol. 2020 Sep;13(9):100804.<br/>Transl Oncol. 2023 Oct 26:39:101803.<br/>Transl Res. 2022.<br/>Universidad de Granada. 2023 Mar 27.<br/>University of Brescia. 2023 Feb 2.<br/>View. 2023 Nov 15.<br/>Acta Biomater. 2023 Apr 21;S1742-7061(23)00220-9.<br/>Acta Pharm Sin B. 2023 Oct;13(10):4253-4272.<br/>Adv Sci (Weinh). 2022 May;9(15):e2105894.<br/>Biomed J. 2020 Aug;43(4):368-374.<br/>Br J Pharmacol. 2021 Jun;178(12):2496-2515.<br/>Cancer Lett. 2024 Feb 6:587:216696.<br/>Cancer Res. 2023 Jun 16;CAN-22-3346.<br/>Chem Biol Interact. 2023 Nov 22:110816.<br/>Heliyon. June 2022, e09643.<br/>Int J Cancer. 2024 Jul 15;155(2):324-338.<br/>Int J Nanomedicine. 2023 Jul 19.<br/>J Mol Med (Berl). 2019 Aug;97(8):1183-1193.<br/>J Pharmacol Exp Ther. 2018 Oct;367(1):20-27.<br/>JCI Insight. 2022 Oct 13;e159419.<br/>Molecules. 2023 Nov 12, 28(22), 7552.<br/>Onco Targets Ther. 2019 Jun 12;12:4585-4593. <br/>Oncol Lett. 2023 Sep 20.<br/>Oncotarget. 2017 Oct 6;8(52):90185-90196. <br/>PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. <br/>SSRN. 2024 Mar 14.<br/>Urol Oncol. 2021 Mar;39(3):194.e1-194.e7.<br/>[1]Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80.<br/>[2]Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194.<br/>[3]Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18(2):198-206<br/>[4]Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30(7):574-589.
Smiles	NC(C=CN1[C@H]2C(F)(F)[C@H](O)[C@@H](CO)O2)=NC1=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY 188011
Lieferbar
Product Description	Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].
StorageTemperature	4°C (Powder, protect from light)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	263.20
Clinical Information	Launched
Manufacturers Research Area	Cancer
Solubility	DMSO : 250 mg/mL (ultrasonic)\|Ethanol : 12.5 mg/mL (ultrasonic)\|H2O : 6.25 mg/mL (ultrasonic; warming)
Target	Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog
Manufacturers Target	Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog
Manufacturers Pathway	Apoptosis; Autophagy; Cell Cycle/DNA Damage
Manufacturers Product type	Reference compound

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-17026-500mg-safety-datasheet.pdf